| First Author | Xu C | Year | 2019 |
| Journal | J Immunol | Volume | 203 |
| Issue | 8 | Pages | 2141-2149 |
| PubMed ID | 31541023 | Mgi Jnum | J:280380 |
| Mgi Id | MGI:6364673 | Doi | 10.4049/jimmunol.1900707 |
| Citation | Xu C, et al. (2019) Identification of a Novel Role for Foxo3 Isoform2 in Osteoclastic Inhibition. J Immunol 203(8):2141-2149 |
| abstractText | Foxo3 acts as an important central regulator that integrates signaling pathways and coordinates cellular responses to environmental changes. Recent studies show the involvement of Foxo3 in osteoclastogenesis and rheumatoid arthritis, which prompted us to further investigate the FOXO3 locus. Several databases document FOXO3 isoform2, an N-terminal truncated mutation of the full-length FOXO3 However, the biological function of FOXO3 isoform2 is unclear. In this study, we established a conditional allele of Foxo3 in mice that deletes the full-length Foxo3 except isoform2, a close ortholog of the human FOXO3 isoform2. Expression of Foxo3 isoform2 specifically in macrophage/osteoclast lineage suppresses osteoclastogenesis and leads to the osteopetrotic phenotype in mice. Mechanistically, Foxo3 isoform2 enhances the expression of type I IFN response genes to RANKL stimulation and thus inhibits osteoclastogenesis via endogenous IFN-beta-mediated feedback inhibition. Our findings identify, to our knowledge, the first known biological function of Foxo3 isoform2 that acts as a novel osteoclastic inhibitor in bone remodeling. |
